Denali Therapeutics

Denali Therapeutics is a biotechnology company dedicated to the development and discovery of treatments for neurodegenerative diseases. The company's development programs include the LRRK2 inhibitor program, which focuses on developing brain-penetrant small molecule LRRK2 inhibitor candidates for Parkinson's disease. Key products include DNL201, DNL151, DNL747, Antibody Transport Vehicle (ATV), and Enzyme Transport Vehicle (ETV), among others.